利伐沙班是治疗什么的药物？

, mainly exerts an anticoagulant effect by inhibiting the activity of coagulation factor

Indications for Rivaroxaban:

1. For adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. For use in adult patients with non-valvular atrial fibrillation who have one or more risk factors (such as congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

In addition, adverse reactions after taking rivaroxaban on the market:

Because these reactions arise from spontaneous reporting (in an uncertain population size), their frequency and causal relationship to drug exposure often cannot be accurately assessed.

Blood and lymphatic system diseases: agranulocytosis, thrombocytopenia;

Intestinal diseases: retroperitoneal bleeding;

Hepatobiliary diseases: jaundice, cholestasis, hepatitis (including liver cell damage);

Immune system diseases: hypersensitivity, anaphylaxis, anaphylactic shock, angioedema;

Nervous system diseases: cerebral hemorrhage, subdural hematoma, epidural hematoma, hemiparesis.

Clinical features of rivaroxaban: oral administration, no injection required, 10 mg, once a day; rapid onset of action; high bioavailability; no need to adjust dosage based on age, gender, weight, race, etc.; no need for routine coagulation function monitoring; medication is not affected by food.

Large clinical studies have shown that compared with enoxaparin, it can further reduce the incidence of venous thromboembolic events after hip or knee replacement; its safety profile is equivalent to enoxaparin. Rivaroxaban is effective, safe and easy for clinical application for postoperative VTE prevention, and may become an ideal choice for VTE prevention.